Arboretum Ventures, a venture capital firm specialising in early-stage private company investments, has announced the final closing of its second investment fund with commitments totali
Arboretum Ventures, a venture capital firm specialising in early-stage private company investments, has announced the final closing of its second investment fund with commitments totaling USD73m.
The latest fund follows Arboretum’s USD24m debut fund, which closed in 2005.
The firm remains focused on investing in promising healthcare and life science companies across the US.
As with the first fund, Arboretum Ventures II is operated by managing directors Jan Garfinkle and Tim Petersen, with the support of five additional investment and professional staff.
‘We are very pleased to have attracted a number of new institutional investors to Arboretum Ventures II, including foundations, pension funds and fund of funds, in addition to many returning institutional and high net worth individual investors,’ says Garfinkle.
Within the healthcare and life sciences sector, Arboretum focuses on medical device, diagnostic and healthcare information technology companies that can achieve key company development milestones in a capital efficient manner.
Arboretum invests across the US, with a particular interest in the Midwest.
Successful companies from the first fund include HealthMedia (acquired by Johnson & Johnson) and Asterand (traded on the London Stock Exchange), as well as a number of privately held companies.
Arboretum has now made investments in 17 companies across its two funds, including its most recent investment in Aptus Endosystems, a medical device company based in Sunnyvale, CA.
